Patient characteristics
| Characteristics . | Allo-HCT in CR1 . | CTx in CR1 . | All patients . | P* . |
|---|---|---|---|---|
| No. of patients | 494 | 1535 | 2029 | |
| Median age, y | 42 | 53 | 50 (16-70) | < .001 |
| Cytogenetic risks (SWOG) | < .001 | |||
| Favorable, n (%) | 29 (6) | 360 (23) | 389 (19) | |
| Intermediate, n (%) | 272 (55) | 777 (51) | 1049 (52) | |
| Unfavorable, n (%) | 115 (23) | 246 (16) | 361 (18) | |
| Unknown, n (%) | 78 (16) | 152 (10) | 230 (11) | |
| FAB | < .001 | |||
| M1, 2, 4, 5, n (%) | 339 (81) | 1345 (93) | 1684 (90) | |
| M0, 6, 7, n (%) | 81 (19) | 104 (7) | 185 (10) | |
| WBC count | .123 | |||
| ≤ 20 000 μ/L, n (%) | 303 (65) | 887 (61) | 1190 (62) | |
| > 20 000 μ/L, n (%) | 163 (35) | 570 (39) | 733 (38) | |
| Remission induction courses | < .001 | |||
| 1 course, n (%) | 340 (69) | 1276 (83) | 1616 (80) | |
| 2 courses, n (%) | 154 (31) | 259 (17) | 413 (20) | |
| Dysplasia | < .001 | |||
| No, n (%) | 337 (68) | 1264 (83) | 1601 (79) | |
| Yes, n (%) | 156 (32) | 268 (17) | 424 (21) |
| Characteristics . | Allo-HCT in CR1 . | CTx in CR1 . | All patients . | P* . |
|---|---|---|---|---|
| No. of patients | 494 | 1535 | 2029 | |
| Median age, y | 42 | 53 | 50 (16-70) | < .001 |
| Cytogenetic risks (SWOG) | < .001 | |||
| Favorable, n (%) | 29 (6) | 360 (23) | 389 (19) | |
| Intermediate, n (%) | 272 (55) | 777 (51) | 1049 (52) | |
| Unfavorable, n (%) | 115 (23) | 246 (16) | 361 (18) | |
| Unknown, n (%) | 78 (16) | 152 (10) | 230 (11) | |
| FAB | < .001 | |||
| M1, 2, 4, 5, n (%) | 339 (81) | 1345 (93) | 1684 (90) | |
| M0, 6, 7, n (%) | 81 (19) | 104 (7) | 185 (10) | |
| WBC count | .123 | |||
| ≤ 20 000 μ/L, n (%) | 303 (65) | 887 (61) | 1190 (62) | |
| > 20 000 μ/L, n (%) | 163 (35) | 570 (39) | 733 (38) | |
| Remission induction courses | < .001 | |||
| 1 course, n (%) | 340 (69) | 1276 (83) | 1616 (80) | |
| 2 courses, n (%) | 154 (31) | 259 (17) | 413 (20) | |
| Dysplasia | < .001 | |||
| No, n (%) | 337 (68) | 1264 (83) | 1601 (79) | |
| Yes, n (%) | 156 (32) | 268 (17) | 424 (21) |
Allo-HCT indicates allogeneic hematopoietic cell transplantation; CTx, chemotherapy; SWOG, Southwest Oncology Group; FAB, French-American-British; and WBC, white blood cell.
Comparing “Allo-HCT in CR1” with “CTx in CR1.”